Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor.

Zou HY, Li Q, Lee JH, Arango ME, Burgess K, Qiu M, Engstrom LD, Yamazaki S, Parker M, Timofeevski S, Cui JJ, McTigue M, Los G, Bender SL, Smeal T, Christensen JG.

Mol Cancer Ther. 2012 Apr;11(4):1036-47. doi: 10.1158/1535-7163.MCT-11-0839. Epub 2012 Mar 2.


Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.

Cullinane C, Dorow DS, Jackson S, Solomon B, Bogatyreva E, Binns D, Young R, Arango ME, Christensen JG, McArthur GA, Hicks RJ.

J Nucl Med. 2011 Aug;52(8):1261-7. doi: 10.2967/jnumed.110.086967. Epub 2011 Jul 15.


PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity.

Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, Painter CL, Wong A, Kraynov E, Arango ME, Mehta PP, Popoff I, Casperson GF, Los G, Bender S, Anderes K, Christensen JG, VanArsdale T.

Clin Cancer Res. 2010 Nov 1;16(21):5177-88. doi: 10.1158/1078-0432.CCR-10-1343. Epub 2010 Sep 9.


PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.

Zhang C, Yan Z, Painter CL, Zhang Q, Chen E, Arango ME, Kuszpit K, Zasadny K, Hallin M, Hallin J, Wong A, Buckman D, Sun G, Qiu M, Anderes K, Christensen JG.

Clin Cancer Res. 2009 Jul 15;15(14):4630-40. doi: 10.1158/1078-0432.CCR-08-3272. Epub 2009 Jul 7.


Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor models.

Zhang C, Yan Z, Arango ME, Painter CL, Anderes K.

Clin Cancer Res. 2009 Jan 1;15(1):238-46. doi: 10.1158/1078-0432.CCR-08-0897.


Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.

Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, Grant S, Ninkovic S, Chen P, Nichols T, O'Connor P, Anderes K.

Mol Cancer Ther. 2008 Aug;7(8):2394-404. doi: 10.1158/1535-7163.MCT-07-2391.


Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy.

Zhang C, Lundgren K, Yan Z, Arango ME, Price S, Huber A, Higgins J, Troche G, Skaptason J, Koudriakova T, Nonomiya J, Yang M, O'Connor P, Bender S, Los G, Lewis C, Jessen B.

Mol Cancer Ther. 2008 Apr;7(4):818-28. doi: 10.1158/1535-7163.MCT-07-0440.


Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22.


An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG.

Cancer Res. 2007 May 1;67(9):4408-17.


An ErbB2-Muc4 complex in rat ocular surface epithelia.

Swan JS, Arango ME, Carothers Carraway CA, Carraway KL.

Curr Eye Res. 2002 May;24(5):397-402.


Synthesis and secretion of Muc4/sialomucin complex: implication of intracellular proteolysis.

Komatsu M, Arango ME, Carraway KL.

Biochem J. 2002 Nov 15;368(Pt 1):41-8.


Production and localization of Muc4/sialomucin complex and its receptor tyrosine kinase ErbB2 in the rat lacrimal gland.

Arango ME, Li P, Komatsu M, Montes C, Carraway CA, Carraway KL.

Invest Ophthalmol Vis Sci. 2001 Nov;42(12):2749-56.


Expression and localization of immunoreactive-sialomucin complex (Muc4) in salivary glands.

Li P, Arango ME, Perez RE, Reis CA, Bonfante EL, Weed D, Carraway KL.

Tissue Cell. 2001 Feb;33(1):111-8.


Supplemental Content

Loading ...
Support Center